South Africa

At a Glance     Contact

South Africa

An introduction to Ranbaxy in South Africa Ranbaxy (S.A.) (Pty) Ltd – South Africa, a wholly owned subsidiary of Ranbaxy, was set up in 1998 There has been a constant effort to differentiate Ranbaxy from the myriad of other generic manufacturers by establishing the corporate heritage and the vision of becoming a research based international pharmaceutical company During 2006 Ranbaxy acquired Be-Tabs with the turover US $ ~30 Mn, and thus became the 5th largest generic company in South Africa The product portfolio is divided into three strategic areas: Acute, Chronic and OTC. The acute products contribute the majority of the Company’s turnover and include Anti-Infectives and Anti-fungals Ranbaxy's joint-venture with Community Investment Holdings (South Africa), “Sonke Pharmaceuticals (Pty) Ltd”, (Sonke) markets and sells Ranbaxy’s range of Anti-retroviral products in South Africa and other African markets   At a Glance   Year of Setup 1996 Team Size 52 Total No. of Molecules Ranbaxy + Local tie ups 27 Brands Lead Molecules Cefpodoxime; Cefuroxime; Co-Amoxiclav; Simvastatin; Ranamp Presence in Therapeutic Segments Anti-infectives; CNS; Cardiovascular; OTC

 

Contact Details

Address 3rd Floor Outspan House 1006 Lenchen House Centurion South Africa Person Saxen Van Coller Phone +27 12 643 2010 Fax +27 12 643 2001 Email saxen.vancoller@ranbaxy.com